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Abstract  34 
Protein-tyrosine phosphatase 1B (PTP1B, EC 3.1.3.48) is an important regulator of insulin 35 
signalling. Herein, we employed experimental and computational biology techniques to 36 
investigate the inhibitory properties of phenolics, identified from four in vitro gastrointestinal 37 
digested (IVGD) soft fruits, on PTP1B. Analysis by LC-MS/MS identified specific phenolics 38 
that inhibited PTP1B in vitro. Enzyme kinetics identified the mode of inhibition, while 39 
dynamics, stability and binding mechanisms of PTP1B-ligand complex were investigated 40 
through molecular modelling, docking, molecular dynamics (MD) simulations, and 41 
MM/PBSA binding free energy estimation. IVGD extracts and specific phenolics identified 42 
from the four soft fruits inhibited PTP1B (P<0.0001) activity. Among the phenolics tested, 43 
the greatest inhibition was shown by malvidin-3-glucoside (P<0.0001) and gallic acid 44 
(P<0.0001). Malvidin-3-glucoside (Ki=3.8 µg/mL) was a competitive inhibitor and gallic 45 
acid (Ki=33.3 µg/mL) a non-competitive inhibitor of PTP1B. Malvidin-3-glucoside exhibited 46 
better binding energy than gallic acid and the synthetic inhibitor Dephostatin (-7.38>-6.37 >-47 
5.62 kcal/mol) respectively. Principal component analysis demonstrated malvidin-3-48 
glucoside PTP1B-complex occupies more conformational space where critical WPD-loop 49 
displayed a higher degree of motion. MM/PBSA binding free energy for malvidin-3-50 
glucoside to PTP1B was found to be higher than other complexes mediated by Van der Waals 51 
energy rather than electrostatic interaction for the other two inhibitors (-80.32 ± 1.25 > -40.64 52 
± 1.43 > -21.63±1.73 kcal/mol) respectively. Altogether, we have established novel insights 53 
into the specific binding of dietary phenolics and have identified malvidin-3-glucoside as a 54 
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1. Introduction 68 
Protein tyrosine phosphatase-1B (PTP1B, EC 3.1.3.48) encoded by the PTPN1 gene is a 69 
therapeutic drug target for type-2 diabetes mellitus (T2DM). PTPN1 plays a pivotal role in 70 
metabolic signalling pathways of cell proliferation, differentiation and cell motility by the 71 
coordinated reversible tyrosine phosphorylation of protein-tyrosine phosphatases (PTPs) and 72 
kinases (PTKs) [1,2]. PTP1B dephosphorylates the insulin receptor (IR) and insulin receptor 73 
substrate (IRS), and acts as the negative regulator of the insulin-stimulated signal 74 
transduction pathway [3]. Therefore, pharmacological agents that inhibit PTP1B activity have 75 
the potential to augment and prolong the action of insulin, providing therapeutic opportunities 76 
for the treatment of T2DM [4]. To date, more than 300 natural PTP1B inhibitors have been 77 
identified  either from natural resources or derived from the structural optimization of natural 78 
products with the therapeutic potential for the prevention of T2DM [5]. Soft fruits including 79 
berries are gaining more attention because of their naturally rich content of bioactive 80 
compounds such as phenolic acids, flavonoids, and anthocyanins, some of which have been 81 
shown to be PTP1B inhibitors [5,6]. The major dietary sources of these phenolics are fruits, 82 
beverages (fruit juice, tea, coffee), vegetables and cereals where the total intake is estimated 83 
to be roughly ∼1 g/day [7]. The dietary intake of anthocyanin’s, as reported in the 2007-2008 84 
NHANES (National Health and Nutrition Examination Survey), has been estimated to be 85 
approximately 11.6 ± 1.1 mg/day for individuals aged ≥20 years and the USDA flavonoid 86 
database identifies berries (20%) as the predominant source of dietary phenolics or 87 
anthocyanins [8].  88 
Given the reported inhibitory effect of soft fruit phenolics as PTP1B inhibitors, the 89 
dietary intake of soft fruits and their bioactive compounds may be beneficial in the 90 
management of T2DM. Moreover, natural bioactive compounds derived from plants are 91 
generally less toxic than those derived from synthetic sources and provide a valuable basis for 92 
5 
 
the development of clinical drug candidates to be used in the treatment of T2DM [9]. A 93 
recent study by Xiao et.al [9] suggested that anthocyanins from raspberries inhibit PTP1B, 94 
and that the phenolic compound ellagic acid showed the highest inhibition among all the 95 
compounds tested. If the therapeutic benefit of these natural soft fruit phenolics is to be 96 
exploited to their maximum, it is important to understand their mechanism of action as 97 
inhibitors of PTP1B. Integrative structural modelling, molecular docking and molecular 98 
dynamics (MD) simulation have been routinely used for this purpose [10]. These powerful 99 
computational approaches are widely used in the structural determination, conformational 100 
changes, protein engineering and rational drug design of the target molecules [11].  101 
The objective of this study was to identify the key bioactive compounds from four 102 
different in vitro gastrointestinal digested (IVGD) soft fruit extracts and to determine if they 103 
can inhibit human PTP1B in vitro at a physiologically relevant concentration. Different soft 104 
fruits were selected for their diverse phytophenol profiles determined by LC-MS/MS and 105 
then IVGD in order to study the PTP1B inhibiting properties of the bio-accessible and 106 
bioactive natural compounds. During the digestion of the soft fruit many metabolites will be 107 
changed or released. Therefore, to help determine what metabolites are crossing over into the 108 
blood to interact with the PTB1B’s we used an IVGD model to mimic the early stages of 109 
digestion and then LC-MS/MS to identify the metabolites as described in detail in our 110 
previous study [12]. We examined the kinetics of the reaction between the enzyme and 111 
substrate at different concentrations to determine the binding modes of the inhibiting 112 
compounds. We also performed molecular docking and dynamics to locate the enzymes 113 
active binding site to ascertain the essential amino acid residues for a significant ligand 114 
binding and to identify any conformational changes of the compounds upon the IVGD. The 115 
highly charged nature of the catalytic domain of PTP1B and the structural homogeneity of the 116 
active and secondary binding sites in PTPs makes it a challenging task for designing drug-117 
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like PTP1B inhibitors as oral agents [5]. Therefore, in silico studies were performed to 118 
overcome the challenges in identifying and designing natural PTP1B inhibitors from the 119 
selected soft fruits, which may prove efficient and safe as clinical drugs for the treatment and 120 
management of T2DM and/or related metabolic disorders.  121 
 122 
2. Materials and methods 123 
2.1 Soft fruits (berries and currants) selection and sample preparation  124 
Green currants (Ribes nigrum) Vertii variety and Black currants (Ribes nigrum L.) Ojebyn 125 
variety were kindly provided by the James Hutton Institute, Dundee, UK. Local wild 126 
bilberries were picked from one season’s growth in one area from Aberdeenshire, UK. Soft 127 
fruits were vacuum-freeze dried (Freezone vacuum Freeze dryer, Labconco, USA) followed 128 
by freeze-milling (Freezer mill Spex CertiPrep 6800, UK) and were then crushed into 129 
powder, vacuum-sealed and stored in -70 °C until further use. Mirtoselect® is a standardized 130 
extract of bilberries (manufactured by Indena S.p.A., Milan, Italy), prepared by an industrial 131 
process to ensure a reproducible anthocyanin composition (36%, w/w). Predominant 132 
anthocyanin constituents of Mirtoselect are delphinidin-3-galactoside, delphinidin-3-133 
glucoside, delphinidin-3-arabinoside, cyanidin-3-galactoside and cyanidin-3-glucoside 134 
(Indena datasheet). Other anthocyanins present include cyanidin-3-arabinoside, petunidin-3-135 
galactoside, petunidin-3-glucoside, petunidin-3-arabinoside, peonidin-3-galactoside, 136 
peonidin-3-glucoside, peonidin-3-arabinoside, malvidin-3-galactoside, malvidin-3-glucoside, 137 
and malvidin-3-arabinoside. Mirtoselect also contains other phenolic compounds (phenolic 138 
acids, flavonols, proanthocyanidins; ~18%), as well as carbohydrates and aliphatic organic 139 
alcohols (~29%), fats (~0.04%), nitrogen compounds (~1%), ash (~0.7%), with the remaining 140 
15% undefined. The main sugar composition of the Mirtoselect® is fructose 13%, glucose 141 
14%; and sucrose 4% (w/w).  142 
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2.2 Chemicals and reagents 143 
Human-active PTP1B enzyme (Product No. SRP0212) was purchased from Sigma Aldrich, 144 
Germany, and the substrate pNPP (p-Nitrophenyl phosphate: Product No. P0757S) was 145 
purchased from New England Biolabs, UK. Malvidin-3-glucoside (0911S), cyanidin-3-146 
glucoside (0915S) and delphinidin-3-glucoside (0936) were from Extrasynthese, France. 147 
Cyanidin (74397), delphinidin (43725), cyanidin-3-galactoside (91635), delphinidin-3-148 
galactoside (04301) protocatechuic acid (0393-05-09), vanillic acid (94770), protocatechuic 149 
aldehyde (D108405), ferulic Acid (Fur1791), 4-hydroxybenzaldehyde (144088-50), 150 
chlorogenic acid (C3878), gallic acid (G7384), synergic acid (S6881), resveratrol (R5010) 151 
were purchased from Sigma-Aldrich, UK. Malvidin (80093), malvidin-3-galactoside (80600), 152 
cyanidin-3-arabinoside (89614) were purchased from PhytoLab, Germany.  153 
For the PTP1B assay and in vitro gastrointestinal digestion, all materials were standard 154 
analytical grade. The following reagents/chemicals were purchased from Sigma-Aldrich, UK; 155 
Dithiothreitol (DTT, product no. D0632), Tris-HCl (T5941), 2-betamercaptoethanol 156 
(M6250), Sodium orthovanadate (NavO4, S6508), Potassium chloride (P5405), monobasic 157 
potassium phosphate (P9791), sodium bicarbonate (S5761), magnesium chloride hexahydrate 158 
(M2393), ammonium carbonate (379999), calcium chloride dihydrate (C7902), amylase from 159 
porcine- Type VI-B (A3176), pepsin from porcine (P7000), pancreatin from porcine pancreas 160 
(P1750), Bile Extract Porcine (B8631). The chemicals/reagents purchased from Fisher 161 
Scientific, UK were Ethylenediaminetetraacetic acid (EDTA, 10628203), Sodium Chloride 162 
(S/3160/60), Hydrochloric acid (H/1000/PB17) and Sodium hydroxide (S/4920/60). 163 
 164 
2.3 PTP1B inhibition assay 165 
The inhibition assay was performed as described by Uddin et.al. [1] with minor 166 
modifications. PTP1B assay buffer (pH 7.2) was made using 1 mM DTT, 1 mM EDTA, 25 167 
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mM Tris-HCl and 2 mM β-mercaptoethanol. The assay was run with a total volume of 100 168 
μL in a 96-well microplate by adding human-active PTP1B enzyme (l μg) and 40 mM p-NPP 169 
in the assay buffer with or without test samples. Incubation was done for 30 min at 37 °C and 170 
the reaction was terminated using 2 M NaOH (100 μL). Absorbance was measured at 405 nm 171 
to estimate the amount of produced p-nitrophenol. Non-enzymatic hydrolysis of p-NPP was 172 
corrected by measuring the absorbance increase recorded from the blank. 173 
 174 
2.4  In vitro gastrointestinal digestion (IVGD) model 175 
The IVGD was performed as described before by Barik et al. [12]. Briefly, the IVGD consists 176 
of three important phases, which mimics the human alimentary canal starting with (I) oral 177 
phase that contains Simulated Salivary fluid (SSF, pH 7) followed by (II) gastric phase- 178 
simulated gastric fluid (SGF, pH 3) and (III) Intestinal phase- simulated intestinal fluid (SIF, 179 
pH 7). The simulated digestion stock fluids were made up of with electrolytes, enzymes, and 180 
water, filter sterilised using 0.22 μm filter, pH adjusted with 1 M NaOH or 1 M HCl and 181 
stored at 4 °C. CaCl2 was added to the mixture on the day of use and not to the simulated 182 
digestion stock fluids. The working solutions were diluted 4:1 (in distilled water) and the 183 
enzyme activities were in units per mL of final digestion mixture rather than secretion 184 
activity unless stated otherwise. A control sample was also included with the same 185 
composition of electrolyte mixture, enzymes, and conditions but without any soft fruit 186 
extracts. 187 
 188 
2.5 Phytochemical analysis 189 
Phytochemical analysis of the IVGD soft fruit extracts was performed using Liquid 190 
chromatography tandem mass spectrometry (LC-MS/MS) as described in detail in our 191 
previous study [12]. Phytochemical extractions were performed by three methods specifically 192 
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optimized for 200 anthocyanidins (aglycones), anthocyanins (glycosides) and ‘other 193 
phenolics’. 194 
 195 
2.6 Statistical Analysis 196 
All the samples were run in triplicate and the results were presented as mean ± standard 197 
error of three independent experiments done on separate days, unless otherwise indicated. 198 
Statistical analysis was performed using GraphPad Prism 5.04 for Windows. The data were 199 
analyzed using One-Way-Analysis of Variance (ANOVA) of Tukey’s multiple comparisons 200 
test to compare within the groups for the PTP1B assay of soft fruits. Dunnet’s multiple 201 
comparison (One-way ANOVA) test compared to single control was used for analysing the 202 
PTP1B inhibition activity of individual compounds. Enzyme kinetics study was evaluated 203 
using SigmaPlot (version 13.0) software made for Windows 10. 204 
 205 
2.7 Protein and ligand preparation 206 
The experimentally determined catalytically inactive mutant (C215S) structure of protein 207 
tyrosine phosphatase 1B (PTP1B) bound with two bis (para-phosphophenyl) methane 208 
(BPPM) (PDB ID: 1AAX) was retrieved from RCSB Protein Data Bank (PDB) for our study 209 
[13]. The protein and co-crystallized ligand structures were separated using BIOVIA 210 
Discovery Studio Visualizer (BIOVIA DSV) v4.5. The active site residues involved in ligand 211 
binding from crystal structure were used to define the grid box for docking studies. The 3D 212 
structures of ligands (i.e. gallic acid, malvidin-3-glucoside and dephostatin) were downloaded 213 
from PubChem, prepared and optimized by Automated Topology Builder (ATB) v2.2 [14].  214 
2.8 Molecular docking simulations 215 
In order to understand the mode and strength of ligand bindings, molecular docking 216 
simulation was performed using AutoDockv4.2 [15]. The method of molecular docking was 217 
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adopted from the previously published study of Dehury et.al. [16]. All ligands and the PTP1B 218 
were prepared for docking using AutoDockTools (ADT) v1.5.6. The protein and ligands were 219 
protonated. The default Kollman charges and solvation parameters were allocated to the 220 
protein atoms, whereas, Gasteiger charges were added to each ligand atom. A grid box 221 
comprised of 55×55×55 points spaced by 0.375 Å was centred on the PTP1B residues 222 
covering the active site. The parameters of the Lamarckian Genetic Algorithm (LGA) were: 223 
300 runs, the population size of 150, a crossover rate of 0.80 and 5x106 energy evaluations. 224 
The resultant docked conformations were clustered using a root-mean-square deviation 225 
(RMSD) tolerance of 2.0 Å. The ligand conformation with the lowest free energy of binding 226 
(∆G) and a greater number of H-bonds, chosen from the most favoured cluster was selected 227 
for the protein-ligand studies using BIOVIA DSV and LigPlot+. The best-screened poses 228 
from docking simulation were finally subjected to 50 ns molecular dynamics simulation to 229 
understand the dynamics of protein-ligand interaction at the molecular scale. 230 
 231 
2.9  Molecular Dynamics Simulation 232 
To understand the mechanism of action of receptor-ligand binding, the dynamical 233 
information of static structures was obtained by simulating the internal motions or dynamic 234 
process. MD simulation was run on all the complexes using GROMACS v5.1 software 235 
package [17] and Amber-99SB*-ILDN force field. The topology study of ligands was 236 
obtained using CCPN-Acpype web server (http://webapps.ccpn.ac.uk/acpype/). Each system 237 
was solvated in a cubic box with 1.5 nm box space using TIP3P water model. NaCl (0.15 M) 238 
was added to each cubic box to neutralize each system. These ions replaced the water 239 
molecules which had maximum electrostatic potential. After ionization, the protocol of 240 
energy minimization was employed for 50,000 cycles using the steepest descent algorithm 241 
and terminated upon reaching a maximum force of 1000 kJ mol-1 nm-1. After energy 242 
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minimization, equilibration was performed using NVT and NPT ensemble. First using NVT 243 
ensemble at 300K and then NPT ensemble was employed for 300K and 1 bar pressure, each 244 
for 1000 ps (1 ns). Temperature coupling was done using Berendsen thermostat method and 245 
the pressure was maintained constant by Parrinello-Rahman barostat. All the bond lengths 246 
were constrained using a linear constraint solver (LINCS) algorithm. Fast particle-mesh 247 
Ewald (PME) electrostatics method was employed to treat all the long-range electrostatic 248 
interactions. Finally, all systems were subjected to production MD simulations for 50,000ps 249 
(50 ns) at 300 K and 1 bar pressure.  250 
 251 
2.10 MD Trajectory Analysis 252 
The dynamics stability parameters of each system were investigated by computing the 253 
backbone root mean square deviation (RMSD), the radius of gyration (Rg), Cα root mean 254 
square fluctuation (RMSF) and intermolecular hydrogen bonds (H-bonds) using built-in 255 
modules of GROMACS. Evolution of secondary structure elements of each system was 256 
performed using the MD simulated trajectory file in the VMD program. The 2D plots 257 
generated using GROMACS utility toolkits were rendered using Xmgrace tool. To explore 258 
the conformation heterogeneity in the ensemble of PTP1B-ligand complex structures 259 
generated by MD simulation, clustering analysis was performed with a RMSD cut-off of 0.25 260 
nm using GROMOS clustering approach. The gmx cluster utility tool was used for structural 261 
cluster analysis by the method described by Daura and co-workers [18]. 262 
 263 
2.11 Principal Component Analysis 264 
Principal component analysis (PCA), a well-established dimensionality reduction statistical 265 
method was employed to understand the collective motions of each PTP1B-ligand complex 266 
systems during MD. Trajectory files of MD simulations were utilized to depict the movement 267 
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of ligand bound structures concentrating on the main-chain atoms. The first step was carried 268 
out using gmx covar module of GROMACS package, which calculates and diagonalizes the 269 
covariance matrix from 50 ns MD simulations trajectories [19]. Then a set of eigenvectors 270 
were obtained from the resultant covariance matrix using gmx anaeig program. For a long-271 
term molecular dynamic simulation only the first few modes are able to delineate the global, 272 
collective fluctuations. Therefore, in this study we only considered the first two dominant 273 
principal components (i.e., first and second PCs) to understand the global motion of PTP1B-274 
ligand complexes. 275 
 276 
2.12 MM/PBSA binding free energy calculation of PTP1B-ligand complexes 277 
Molecular mechanics based energy, when coupled with the generalized Born or Poisson-278 
Boltzmann and surface area solvation (MM/GBSA and MM/PBSA) approaches are pivotal to 279 
estimate the interaction free energies of small ligands with biological macromolecules 280 
[20,21]. The main objective of these approaches is to determine the free energy differences 281 
between the bound and unbound states of two molecules or alternatively a comparison of free 282 
energies of the same molecule in two different solvated conformations. In this study, we 283 
employed the MM/PBSA approach employed in g_mmpbsa script compatible with 284 
GROMCAS trajectories to calculate the protein-ligand binding free energies. Binding free 285 
energies calculations was performed from the 200 snapshots (at an equal interval of time) of 286 
MD trajectory from 30 to 50 ns MD simulation during equilibrium phase. In addition, we also 287 
performed per residues decomposition analysis to understand the different energetic terms 288 
contributed by each residue towards binding free energy. The complete protocol for binding 289 
free energy calculation was adopted from a previous study [16].  290 
 291 
3 Results 292 
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3.1 IVGD soft fruits extracts inhibit PTP1B at physiologically relevant concentrations 293 
We studied the effects of the IVGD soft fruit extracts on human PTP1B enzyme activity 294 
in vitro and compared their activity. All the samples were assayed in vitro within the 295 
calculated physiological range of 0.06 to 66 μg mL-1 [22,23]. All the extracts at physiological 296 
relevant concentrations significantly inhibited PTP1B (P<0.0001). IVGD black currants 297 
(DBC) showed higher inhibition when compared to IVGD green currants (DGC); IC50 11.42 298 
μg mL-1 vs IC50 20 μg mL-1 (Fig. 1A) and IVGD Wild type bilberries (DWT) showed higher 299 
inhibition when compared to IVGD Mirtoselect (DMS); IC50 9.71 μg mL-1 vs IC50 19.45 μg 300 
mL-1 (Fig. 1B). Both DBC and DGC showed inhibition of PTP1B at 66 μg mL-1 (60.2%, 301 
P<0.0007 vs 45.7%, P=0.0284, respectively); At 6.6 μg mL-1, DBC did not show any 302 
inhibition (P=0.1729), however, DGC showed a significant inhibition of 44.1% (P=0.0401). 303 
Similarly, the extracts of DWT showed a significant inhibition of PTP1B at 66 μg mL-1 while 304 
DMS showed no inhibition at the same concentration (71.8%, P<0.0001 vs 27.3%, 305 
P=0.5317). However, at 6.6 μg mL-1, both DWT and DMS showed significant inhibition of 306 
PTP1B (49%, P=0.0069 vs 55.8%, P=0.0017). Sodium Orthovanadate which is a known 307 
inhibitor of PTP1B inhibited the enzyme activity by 47% (20 μM (3.68 µg/mL); P=0.0355). 308 
 309 
3.2 Individual compounds (anthocyanins, anthocyanidins and other phenolics) 310 
identified from the phytochemical analysis of the soft fruit extracts inhibit PTP1B 311 
To determine if specific individual anthocyanins, anthocyanidins and other phenolics are 312 
responsible for the inhibition of PTP1B activity by the soft fruit extracts shown in fig. 1, we 313 
selected nineteen compounds based on the phytochemical analysis of the currants by LC-314 
MS/MS (Table 1). Three major anthocyanin aglycones, their glycosides and nine other 315 
phenolics were selected to investigate their independent effect on PTP1B inhibition. Among 316 
the anthocyanin aglycones, cyanidin showed significant inhibition of PTP1B by 29.6% 317 
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(P<0.0001) and delphinidin by 28.49% (P<0.0001) at 66 μg mL-1, whereas, malvidin at the 318 
same concentration did not show any significant inhibition (P=0.9856) compared with the 319 
control (Fig. 2A). Similarly, no significant inhibition was found for the anthocyanin 320 
glucosides; cyanidin-3-glucoside (P=0.2844) and delphindin-3-glucoside (P=0.9956) when 321 
compared with the control. However, malvidin-3-glucoside showed the highest inhibition 322 
(P<0.0001) of PTP1B among all the selected glycosides, which was found to be dose 323 
dependent by 37.7%, 28.6% and 28.1% at 66, 6.6 and 0.66 μg mL-1 respectively. Cyanidin-3-324 
galactoside inhibited PTP1B by 31.6% (P<0.0001) and malvidin-3-galactoside by 28% 325 
(P<0.0001) at 6.6 μg mL-1 compared with the control (Fig. 2A). Gallic acid showed the 326 
highest inhibition of PTP1B compared to the control, which again was dose dependent 327 
(P<0.0001) by 52.9%, 39.2%, 30.8% at 66, 6.6 and 0.66 μg mL-1 respectively. This was 328 
followed by 4-hydroxybenzadehyde by 38.9% (P<0.0001), ferulic acid by 37.7% (P<0.0001), 329 
and resveratrol by 37.3% (P<0.0001) at 66 μg mL-1 (Fig. 2B). Protocatechuic aldehyde was 330 
the only non-anthocyanin phenolic to show no inhibition of PTB1B activity compared to the 331 
control. 332 
 333 
3.3 Enzyme kinetics of malvidin-3-glucoside and gallic acid demonstrated competitive 334 
and non-competitive inhibition to PTP1B respectively 335 
In order to determine the mode of inhibition shown by the dietary phenolics on PTP1B, 336 
we studied the enzyme kinetics of malvidin-3-glucoside (anthocyanin glycoside) and gallic 337 
acid (other phenolics), because these two compounds showed the highest PTP1B inhibition 338 
among the range of selected anthocyanins and other phenolics. Line weaver-Burk plot was 339 
used where a reciprocal of rate of the reaction was plotted against the reciprocal of the 340 
substrate concentration. This determines the inhibitors effect on Km and Vmax. The Ki 341 
(inhibitor constant) was confirmed through a Dixon plot by plotting the reciprocal of the rate 342 
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of reaction against the different concentrations of the compound (Fig. 3). The enzyme 343 
kinetics study of the compounds suggested that malvidn-3-glucoside is a competitive 344 
inhibitor of the substrate pNPP as the Vmax was not affected at different concentrations of 345 
PTP1B, whereas the Km increased. The Dixon plot determined the Ki of malvidin-3-346 
glucoside, which was found to be 3.8 μg mL-1 (Fig. 3 A&B). In contrast, gallic acid showed a 347 
non-competitive inhibition since the increase in substrate concentrations did not intersect the 348 
lines on the y-axis of the Line weaver–Burk plot but intersected at a non-zero point on the 349 
negative x-axis (-Ki) in Dixon plots (Fig. 3 C&D). The Ki of gallic acid was found to be 33.3 350 
μg mL-1. 351 
 352 
3.4 Analysis of molecular docking  353 
To understand the mode and efficacy of binding of the two ligands, malvidin-3-glucoside 354 
and gallic acid with the known three-dimensional structure of the human PTP1B protein, we 355 
employed molecular docking techniques using AutoDock. Dephostatin was used as a positive 356 
control for comparison in the in-silico studies. It is well known that the lower the binding 357 
energy of a ligand, the stronger it binds to the protein. The docking study suggests that 358 
malvidin-3-glucoside has a lower binding energy (-7.38 kcal/mol) than gallic acid (-6.37 359 
kcal/mol), as shown in Table 2. Malvidin-3-glucoside was found to form a total of eight H-360 
bonds through Tyr46, Asp48, Lys120, Asp181, Ser216, Gly220 and Arg221 amino acid 361 
residues (Fig. 4B). Moreover, three residues i.e., Val49, Phe182 and Ala217 displayed 362 
hydrophobic contacts with malvidin-3-glucoside. Gallic acid displayed five strong H-bonds 363 
along with two hydrophobic contacts (Fig. 4A). Among the three ligands, Dephostatin 364 
demonstrated the least binding energy (-5.62 kCal/mol), where Glu115, Phe182, Ser216, 365 
Ala217 and Arg221 residues were predicted to form a tight network of H-bonding (Fig. 4C). 366 
The detailed inter-molecular contacts formed by the ligands with PTP1B are presented in 367 
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Table 2. The docking results of the PTP1B-ligand complexes showed that the investigated 368 
compounds were enclosed in the binding cavity where residues of regulatory loops WPD 369 
loop (Thr177–Pro189), and P loop (His214–Arg221) formed strong inter-molecular contacts. 370 
 371 
3.5 Analysis of MD Trajectories 372 
To measure the intrinsic stabilities of the docked conformations, we performed MD 373 
simulation of three complexes in aqueous solution. The structural changes and flexibility of 374 
each system were computed by various stability parameters including the backbone root 375 
mean-square deviations (RMSDs), radius of gyration (Rg) and Cα-fluctuations (RMSFs) 376 
during 50 ns simulation. The RMSD was calculated by comparing the movement of backbone 377 
atoms with initial coordinates (used for production MD) where, the RMSD of complexes 378 
became stable after 35 ns and were maintained till the end of the simulation (with average 379 
RMSD of ~2.49 Å). During the initial 30 ns, the RMSD reduced to 2.78 Å in all complexes, 380 
later it was found to be stable indicating that they all reached the equilibrium state (Fig. 5A). 381 
The deviations from the average position in terms of RMSD were found to be within ~1.2Å 382 
for all the systems, where, PTP1B-dephostsatin complex showed slightly higher RMSD than 383 
the other two complex systems. The ligands RMSD were within the range of 0.36 to 0.71 Å 384 
(data not shown).  The Rg which evaluates the compactness of the system also depicted a 385 
stable and compact gyradius of ~19.63, 19.72 and 19.81 Å respectively for gallic acid, 386 
malvidin-3-glucoside and dephostatin complexes signifying a consistent shape and size of all 387 
the systems during the simulation (Fig. 5B).  Further, to understand the structural fluctuation 388 
and flexibility of PTP1B complexes we computed the Cα RMSF of each system. The average 389 
RMSFS of Cα atoms in PTP1B complexes were found to be within range of ~2.67 Å, as 390 
shown in Fig. 5C. Altogether the three systems displayed more or less the same trend in 391 
RMSF with minor exceptions in the case of dephostatin complex system. The residues in the 392 
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WPD-loop displayed higher flexibility with high peaks while the catalytic region (P-loop) 393 
exhibited a high degree of rigidity, which signifies that the WPD-loop may experience a 394 
remarkable conformational change. Evolution of secondary structure elements of each system 395 
displayed the helices and strands retained their basic properties throughout the simulation, as 396 
shown in Fig. 5D.  397 
 398 
3.6 Principal Component Analysis (PCA) 399 
To obtain a clear picture of what influences the conformational change of PTP1B 400 
upon bindings of the ligands, we plotted eigenvalues by the diagonalization of the covariance 401 
matrix of the Cα atomic fluctuations. The concerted motions characterized by the first two 402 
eigenvalues (EVs) rapidly declined in amplitude to reach a number of constrained and more 403 
localized fluctuations (Fig. 6A). Indeed, the first two PCs accounted for more than ~80% of 404 
the total motions of the gallic acid, malvidin-3-glucoside and dephostatin complexes 405 
observed from the equilibrium phase of MD simulations, respectively. Among the three 406 
binding modes, the amplitudes of the eigenvalues gallic acid complex were found to be on the 407 
lower side than those of the malvidin-3-glucoside and dephostatin complex (Fig. 6A). 408 
However, comparatively malvidin-3-glucoside complex showed somewhat higher degree 409 
motion as compared to the other two binding modes which was well supported by the 410 
projection of top two EVs in phase space. The 2D projection plot generated all three complex 411 
systems indicated a substantial difference between the PTP1B-inhibitor complexes (Fig. 6B). 412 
Further to shed more insight into the conformational changes of PTP1B upon ligand binding, 413 
the porcupine plots were generated depicting the directions of movements by means of the 414 
extreme projections of MD trajectories on the PC1 and modevectoy.py script in PyMOL (Fig. 415 
6C-E). The direction of arrow reflects the movement of main chain atoms of each amino 416 
acids corresponding direction of movement and the length of the arrow symbolizes the 417 
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strength of the motions. Altogether, the presence of the inhibitors had different effects on the 418 
movement of PTP1B in all three binding modes. The binding of inhibitors not only 419 
suppressed the motion strength, but also changes the motion direction of the WPD-Loop, 420 
which demonstrates that the conformation of the WPD loop has altered to some extent in 421 
malvidin-3-glucoside and the dephostatin complexes. For the gallic acid complex, the motion 422 
strength of the WPD-loop, and P-loop were heavily reduced compared to the other two 423 
systems. These results indicate that binding of the inhibitors results in noteworthy changes in 424 
the conformation in the WPD-loop of PTP1B, which is supported by the RMSF analysis. To 425 
inspect the outcome of the inhibitor bindings on the internal dynamics of PTP1B, the cross-426 
correlation matrices of Cα atoms over their mean positions were calculated from the 427 
equilibrated trajectories for each complex (30-50 ns), as shown in Fig 6F-H. The negative 428 
regions (blue) represent strongly anti-correlated motions between residues, while the positive 429 
regions (red and yellow) describe strongly correlated motions, and the diagonal regions 430 
depict the motion of a particular residue relative to itself. It can be observed from the cross-431 
correlation matrices that a significant difference exists in the movement pattern of three 432 
complex systems, which designates that bindings of inhibitors produce different effects on 433 
the internal dynamics of PTP1B. Hence, it can affirm that binding of the inhibitor results in 434 
substantial effect on the mode of motion in PTP1B where alteration in the relative positions 435 
of key residues often mediated by the internal dynamics. 436 
3.6.1. Free Energy Landscape Analysis 437 
The conformational spaces of the PTP1B complexes were produced to provide important 438 
clues on the conformational changes in the protein by projecting the MD trajectories on the 439 
first two PCs, and the corresponding free energy landscapes, as shown in Fig. 6I-K. The 440 
gallic acid complex only possesses a large single energy basin, while the other two systems 441 
displayed two energy basins which were mainly distributed in two different conformational 442 
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subspaces. The bindings of inhibitor malvidin-3-glucoside and dephostatin to PTP1B induces 443 
the redistribution of conformations, which make the conformation of PTP1B focus on two 444 
different subspaces while presence of inhibitor gallic acid produces only one energy basin 445 
that is mainly distributed in a conformational space. This signifies that, the binding of gallic 446 
acid induces a big conformation change relative to the other two systems. Finally, it can be 447 
concluded that bindings of the inhibitor result in a significant effect on the conformation of 448 
PTP1B. 449 
 450 
3.7 Intermolecular hydrogen-bond and clustering analysis 451 
Furthermore, we calculated intermolecular hydrogen-bonds (H-bonds) over 50 ns MD 452 
simulations of each system to measure the intrinsic stability of PTP1B-inhibitor complexes. 453 
We noticed a variable pattern of H-bonding over the different course of time in all 454 
complexes. The PTP1B-gallic acid complex displayed a higher number of H-bonds with an 455 
average of ~7.87 numbers H-bonds for each frame as a function of simulation time, whereas, 456 
malvidin-3-glucoside represented ~2.77 numbers of H-bonds (Fig. 7A&B). Dephostatin 457 
complex displayed the least number (~1.24) of H-bonds as compared to the other two 458 
complexes (Fig. 7C). The differential pattern of H-bonding in all three PTP1B complexes 459 
may be due to the preferential affinity of the protein towards the inhibitor within the active 460 
pocket and/or due to the conformational change in protein induced by dynamics of loops 461 
associated with binding mechanism process. To explore the conformational heterogeneity in 462 
the ensemble of PTP1B-ligand bound structures obtained from the equilibrated trajectories, 463 
the clustering approach based on RMSD was used. A set of dominant clusters were obtained 464 
from which the top two ranked clusters were taken for further analysis. As evident from Fig. 465 
7D-F, the ligand binding residues were conserved excluding small changes for Dephostatin 466 
(Fig. 7F). This might be due to a slight change in the orientation of ligand and a 467 
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conformational change induced by the loops of PTP1B as confirmed by RMSF analysis. 468 
Furthermore, comparative analysis of pre (Fig. 4) and post-MD analysis of the complexes 469 
(Table 3) revealed that a number of critical H-bonds were broken during the MD simulations 470 
which later reformed through new H-bonds and hydrophobic contacts. 471 
3.8 Binding Free Energy 472 
To appraise binding capabilities of the three inhibitors to PTP1B, we employed the 473 
MM/PBSA method to calculate binding free energies using 200 conformations taken from the 474 
last 20 ns of MD trajectories. The free energies for the binding of gallic acid, malvidin-3-475 
glucoside and dephostatin to PTP1B were computed to be -40.64 ± 1.43, -80.32 ±1.25 and -476 
21.63±1.73 kcal mol-1 respectively (the detailed energetic decompositions are summarized in 477 
Table 4). The free energy for binding of malvidin-3-glucoside to PTP1B was found to be on 478 
the higher side compared with the other two inhibitors. In the case of malvidin-3-glucoside 479 
complex, the driving force was Van der Waal energy (-137.85 ± 1.23 kcal/mol) whereas, 480 
electrostatic interaction plays a decisive role for the binding affinities of gallic acid and 481 
dephostatin towards PTP1B. Van der Waals energy was the dominant driving force along 482 
with solvent accessible surface area (SASA) energy. Among the solvation energy, the non-483 
polar solvation energies were found to be negative, which significantly contributed to the 484 
total binding energies. However, the polar solvation terms oppose the binding and present 485 
unfavourable effects, which were roughly offset by the electrostatic contributions. To 486 
elucidate the roles of discrete amino acid residues in the process of binding to inhibitors, we 487 
computed the per residue-based free energy decomposition analysis. Free energy 488 
decomposition analysis revealed that the active site residue located in the important 489 
regulatory loops contributes significantly to the overall free binding energy of the gallic acid 490 
and malvidin-3-glucoside complexes. For cross-comparison, we calculated the intermolecular 491 
contacts of gallic acid and malvidin-3-glucoside with PTP1B before MD and the top ranked 492 
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conformation obtained from clustering analysis. As shown in Fig. 8 and Fig. 9, Phe182 of 493 
WPD-loop, and the residues Ser215, Ser216, Ala217, Ile219, Gly220 and Arg221 of the P-494 
loop are playing crucial role maintaining the tight anchoring of ligands within the active site 495 
pocket. The NH atom of Ala217 formed a hydrogen bond of the O4 atom with gallic acid 496 
along with a pi-Alkyl contact. Ser215 (mutated catalytic Cys), Ser216, Ile219 and Gly220 497 
formed a strong hydrogen bond (average distance of 2.07) with gallic acid; in contrast 498 
Arg221 formed a hydrophobic contact. Moreover, these residues also contributed greater than 499 
1 kcal/mol to the gallic acid binding. As compared to the gallic acid complex, the malvidin-3-500 
glucoside-PTP1B complex displayed a greater number of non-bonded contacts. The NH-atom 501 
of Val49 near the hydrophobic ring formed strong hydrogen bond with O11 of malvidin-3-502 
glucoside. The Ph2182 of WPD-loop formed Pi-Pi-T-shaped hydrophobic contacts with 503 
malvidin-3-glucoside, while the P-loop residues Ser216, Ala217, Ile219, formed Pi-Alkyl 504 
contacts indicating their preference for binding with the ligand. According to Table 5 and Fig. 505 
9, it can be summarised that the loops are essential for inhibitory activity of PTP1B. 506 
 507 
4 Discussion 508 
PTP1B inhibitors have emerged as novel target drugs for the treatment of obesity and 509 
T2DM [21]. In this study, we have shown that PTP1B activity was inhibited by all the 510 
selected IVGD soft fruit extracts at physiologically relevant concentrations. The soft fruit 511 
extracts were shown to be high in anthocyanins except for DGC. However, all of them 512 
contained substantial amounts of phenolic acids such as benzoic- (e.g. gallic acid, syringic 513 
acid) and cinnamic acids (e.g. ferulic acid). This suggests that in addition to the anthocyanins, 514 
the presence of other phenolics in the soft fruits may be contributing to the inhibitory effect 515 
of the extract on PTP1B. This study looked at the individual selected compounds from the 516 
IVGD soft fruit extracts. It showed that the aglycone cyanidin and delphinidin inhibits 517 
22 
 
PTP1B but not malvidin. However, malvidin-3-glucoside was shown to have the highest 518 
inhibition of PTP1B among the selected anthocyanins and anthocyanidins whereas the 519 
glucosides of cyanidin and delphinidin did not show any inhibition to PTP1B. This suggests 520 
that the presence of the glucose moieties on malvidin, similar to the effects of the methoxyl 521 
groups (functional group consisting of a methyl group bound to oxygen- OCH3) in the ring B 522 
could be responsible for the observed PTP1B inhibitory activity, whereas the presence of a 523 
polar functionality (e.g. hydroxyl group- OH) may not be contributing to the inhibitory 524 
activity in the anthocyanins [24,25]. On the other hand, when we studied other phenolics; 525 
gallic acid was shown to have the greatest PTP1B inhibitory activity, suggesting that 526 
increasing the number of hydroxyl groups in this molecule improved the PTP1B inhibitory 527 
effect [26].  528 
The difference between the inhibitory compounds malvidin-3-glucoside and gallic 529 
acid were initially studied through enzyme kinetics, which suggested that malvidin-3-530 
glucoside inhibited PTP1B in a competitive manner by binding at the active site of the 531 
enzyme; whereas gallic acid showed a non-competitive mode of inhibition indicating that this 532 
inhibitor might bind at other binding sites of PTP1B. To determine the binding sites and 533 
binding energy of these PTP1B inhibitors to PTP1B, in silico molecular docking and 534 
simulation studies were applied in order to determine the orientation, pharmacological 535 
bioactivities, and structure-activity relationships of ligand-protein interactions for the 536 
selectivity of the natural PTP1B inhibitors. The WPD loop plays an important role in the 537 
specificity and affinity of the inhibitors [27]. Docking studies showed that gallic acid and 538 
malvidin-3-glucoside prefer to interact with Ser216, Ala217, Gly220, and Arg221 in the P 539 
loop (His214–Arg221), demonstrating that these inhibitors may reduce the mobility of the 540 
WPD loop towards a more rigid conformation, which in turn inhibits WPD loop closure and 541 
prevents substrate binding [28]. A recent study has also demonstrated that the conformational 542 
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and dynamic features of WPD-loop play a vital key role in providing a smooth entrance for 543 
the inhibitors moving into the binding pocket as well as a favourable microenvironment to 544 
stabilize them [27], which agrees with our findings from this study. Further, the intrinsic 545 
dynamics of proteins are essential for protein function and regulation [29–31]. To explore the 546 
structural and dynamics of PTP1B in complex form, we employed molecular dynamics 547 
simulations for 50 ns in aqueous solution. All the complexes displayed a stable trend in 548 
RMSD and Rg indicating the converged structure and compactness of the systems after MD. 549 
The RMSF values of  a few residues including the N-terminal end, residues positioned 550 
between 111-121 aa, and loops (the P-loop, and WPD-loop) displayed lower RMSF values 551 
which also perfectly correlates with recent MD simulation studies [10]. The probable reason 552 
for this is that these regions are crucial for the binding of the inhibitors through various non-553 
bonded interactions. It also appears that the flexibility or the conformational changes of the 554 
enzyme is greatly affected by the presence of diverse ligands/inhibitors. To explore the 555 
conformational changes and global motion of proteins, the most promising statistical tool 556 
principal components (PCs) analysis was used [16,32]. These results substantiate the previous 557 
MD simulation studies where the conformation of the WPD-Loop undergo a change during 558 
MD simulations, which offers important dynamics evidence for the design and development 559 
of novel small molecules inhibiting the activity of PTP1B [27,33,34].  560 
The molecular mechanics, based on the Poisson-Boltzmann surface area (MM/PBSA) 561 
approach has been widely used to compute binding free energies of ligands/inhibitors/drugs 562 
when coupled with receptors/proteins from MD trajectories [16,35]. MM/PBSA analysis 563 
revealed that the residues in the active sites provide a substantial contribution to bindings of 564 
the inhibitors to PTP1B. Among the non-bonded interactions, the H-bonds followed by the 565 
hydrophobic interactions are the main forces driving the inhibitor-PTP1B bindings. 566 
Additionally, three inhibitors have noticeable differences in structure, and these structural 567 
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variations might have led to the differences in non-bonded interactions between PTP1B and 568 
the inhibitors. Therefore, it is crucial to optimize strong H-bonding and hydrophobic 569 
interactions of inhibitors with PTP1B for the design and development of novel inhibitors to 570 
suppress the activity of PTP1B receptor. A recent computational study also suggested that the 571 
mutation of Arg222/221 at the active site results in a significant decrease in binding affinity, 572 
thereby affirming its role in the binding process [10] which supports our study. Overall, 573 
residues around the active site (including WPD-loop and R-loop) have a more pronounced 574 
effect on the binding free energy. In recent years some PTP1B inhibitors have been 575 
synthesized by chemical methods  however, they possess different side effects [5]. Therefore, 576 
it is necessary to study the mechanisms of interactions of inhibitors with PTP1B at the atomic 577 
level through various biophysical techniques including NMR, XRD or cryo-EM studies for 578 
the development of new and effective drugs with minimal side effects. We expect that further 579 
optimization of these dietary/natural compounds will help in the development of therapeutic 580 
drugs that can efficiently inhibit the activity of PTP1B.  581 
In summary, this study identified specific soft fruit extracts and their dietary 582 
components as significant inhibitors of human PTP1B by employing both experimental and 583 
computational modelling approaches. The in vitro gastrointestinal digestion model shows that 584 
these soft fruit metabolites still actively inhibit PTP1B following digestion. As anthocyanins 585 
are found at high levels in soft fruits such as MS, WT and BC, they may be responsible for 586 
the larger proportion of the PTP1B inhibition that we have observed. However, we cannot 587 
rule out the contribution made by other phenolics, as we have also shown that they also 588 
inhibit PTP1B. Among the phenolic compounds tested from the IVGD soft fruit extracts, it 589 
was shown that malvidin-3-glucoside and gallic acid exhibited the highest PTP1B inhibitory 590 
activities, demonstrating competitive and non-competitive modes of inhibition, respectively. 591 
Furthermore, molecular dynamics simulations, PCA, free energy landscape and binding free 592 
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energy estimations displayed more or less similar chemical scaffolds with distinct selectivity 593 
of malvidin-3-glucoside and gallic acid as PTP1B inhibitors. Both the compounds were found 594 
to be promising PTP1B inhibitors, however, malvidin-3-glucoside displayed a higher number 595 
of intermolecular contacts with higher binding energy than gallic acid suggesting it is the 596 
more effective PTP1B inhibitor. Thus, we have demonstrated an efficient and practical 597 
method to understand the fundamental dynamics, stabilities and identified predominant 598 
factors that drive the binding of the natural inhibitors to PTP1B. Further clinical studies with 599 
the natural compounds as novel PTP1B inhibitors are needed to establish the therapeutic 600 
applications of the identified compounds in the management and treatment of T2DM, which 601 
is a highly prevalent metabolic disorder. 602 
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List of Figures 744 
Figure 1. Effect of in vitro gastrointestinal digested currants on PTP1B inhibition. (A) 745 
DBC vs DGC and (B) DWT vs DMS. EA: Enzyme activity, Control: enzyme control 746 
(without soft fruits) NavO4: Sodium orthovanadate, DBC: IVGD blackcurrants, DGC: 747 
IVGD green currants, DWT: IVGD WT bilberries, DMS: IVGD Mirtoselect. Statistical 748 
significance was determined by One-way ANOVA of Tukey’s multiple comparison tests 749 
using GraphPad Prism 5.0 for Windows 10. Data is the representation of ± SD of three 750 
independent experiments done on separate days. Values without a common letter are 751 
significantly different (P<0.05). 752 
 753 
Figure 2. In vitro inhibition of PTP1B by identified dietary phenolic compounds 754 
independently. (A) Anthocyanins and anthocyanidins, (B) Other phenolics. Enzyme 755 
inhibition by the compounds was determined by percentage inhibition against control 756 
(100% enzyme activity). Samples were run in triplicates and at three different 757 
concentrations (66, 6.6, 0.66 μg mL-1). Data is expressed as ± SD of at least three 758 
independent experiments and the statistical analysis was done by one-way analysis of 759 
variance of Dunnet’s test compared against single control using GraphPad Prism 5.0 for 760 
Windows 10. The control was α-amylase activity without the addition of any compound 761 
and the positive control was NaVO4 (Sodium Orthovanadate). 762 
 763 
Figure 3. Enzyme kinetics of Malvidin-3-glucoside and Gallic acid. Line-weaver Burk and 764 
Dixon plot of malvidin-3-glucoside (A&B)-competitive inhibition and Gallic acid (C&D)-765 




Inhibition kinetics of compounds were expressed in Lineweaver-Burk and Dixon plots as the 768 
mean reciprocal of initial velocity for n=3 replicates at each substrate concentration. The 769 
inhibition constant Ki value was determined from the x-axis value at the point of the 770 
intersection of the three lines. The graphs were generated using SigmaPlot 13.0 statistical 771 
software for Windows 10. 772 
 773 
Figure 4. Illustration of the interaction of Gallic acid (A), Malvidin-3-glucoside (B) and 774 
Dephostatin (C) with the catalytically inactive mutant (C215S) crystal structure of PTP1B 775 
(PDB ID: 1AAX) obtained from docking simulations using AutoDock. The hydrogen-bond 776 
form forming amino acids are shown in a ball and stick representation (labelled in green) 777 
and the atomic distance in a green dotted line (in Angstrom unit). The hydrophobic contact 778 
forming residues are displayed in red-semi circles (labelled in black). The interaction is 779 
calculated using the LigPlot+ program. 780 
 781 
Figure 5. Intrinsic stabilities of the PTP1B complex systems with respect to time during 782 
50 ns MD simulation. (A) Backbone root mean squared deviations (RMSD) of PTP1B-783 
gallic acid (black curve), PTP1B-Malvidin-3-glucoside (red curve) and PTP1B-784 
Dephostatin complex (green curve) over the time scale of 50 ns. (B) The compactness of 785 
the protein-ligand systems assessed through computing the radius of gyration. (C) The 786 
flexibility of each complex system computed through the root mean squared fluctuations 787 
of Cα-atoms as a function of time. (D-F) Evolution of secondary structure elements of the 788 
PTP1B-complexes over the time scale of 50 ns. The image was plotted using the MD 789 
trajectories of PTP1B-complexes through VMD. 790 
Figure 6. Principal component analysis (PCA) of the PTP1B complex trajectories (A&B), 791 
Porcupine plot corresponding to PC1 obtained by performing PCA on MD trajectories of 792 
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PTP1B complexes (C-E), The cross-correlation matrixes of fluctuations of the PTP1B-793 
complexes during 50 ns MD (F-H) and Free energy landscapes plots (I-K). (A) The first 20 794 
eigenvectors of the covariance matrix of each complex (Black: PTP1B-gallic acid 795 
complex, Red: PTP1B-Malvidin-3-glucoside and Green: PTP1B-dephostatin complex) and 796 
the lines with diamond symbol represent the cumulative sum of the contribution to the 797 
total fluctuations. (B) Projection of PTP1B atoms in phase space along the first two 798 
principal eigenvectors (EV1 and EV2). (C) PTP1B-gallic acid complex, (D) PTP1B-799 
Malvidin-3-glucoside and (E) PTP1B-dephostatin complex. The red arrow represents the 800 
direction of motion and the length characterizes the amplitude of motion. The cross-801 
correlation matrixes are calculated as a function of Cα atom distance between residue 802 
pairs. The extent of correlated motions is shown using color-coded from red to blue 803 
(correlation to anti-correlation) for (F) PTP1B-gallic acid complex, (G) PTP1B-malvidin-804 
3-glucoside, and (H) PTP1B-dephostatin. Projections of Free energy landscape of (I) 805 
PTP1B-gallic acid complex, (J) PTP1B-malvidin-3-glucoside, and (K) PTP1B-dephostatin 806 
conformational space onto PC1 and PC2 produced from PCA of MD trajectories. The FEL 807 
was constructed using gmx sham module of GROMACS and the image was prepared using 808 
Mathematica. 809 
 810 
Figure 7. The stability of the PTP1B-inhibitor complexes computed through 811 
intermolecular H-bonds formed between the atom pairs of the protein PTP1B and ligands 812 
with respect to time (A-C) and Structural view of the top ranked cluster obtained from 813 
clustering of MD trajectories of PTP1B complexes (D-F).  814 
(A) The black timeline graph depicts the PTP1B-gallic acid complex; (B) The red timeline 815 
displays the PTP1B-malvidin-3-glucoside, and (C) the green timeline portrayed PTP1B-816 
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dephostatin complex over 50 ns MD. (D) Top ranked cluster of PTP1B-gallic acid 817 
complex, (E) Top ranked cluster of PTP1B-Malvidin-3-glucoside and (F) Top ranked 818 
cluster of PTP1B-dephostatin complex. The H-bonds are shown in dotted lines. The WPD 819 
loop is marked in magenta and P loop marked in red. 820 
 821 
Figure 8. Residue based free energy decomposition of free energy of the important ligand 822 
binding residues of PTP1B complexes. The important residues of the regulatory WPD and 823 
P-loop are taken into consideration for plotting this graph. The green line trend depicts the 824 
contribution made by these important residues towards total binding free energy of gallic 825 
acid (B) the red timeline shows for malvidin-3-glucoside, and (C) the red trend portrays 826 
for dephostatin. 827 
 828 
Figure 9. Comparative analysis of the 2-Dimensional representation of binding site residues 829 
of Gallic acid and malvidin-3-glucoside with PTP1B before and after molecular dynamics 830 
simulation. The top ranked cluster obtained from clustering analysis from MD trajectories of 831 
PTP1B-complexes is used for inter-molecular contact analysis using BIOVIA DSV.  The 832 
ligand is shown in stick representation and the intermolecular contact forming residues are 833 
































          

































































































































































































































Figure 4 891 
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List of Tables 1008 
Table 1. Selected phenolic compounds from the four soft fruit extracts for further 1009 
analysis. 1010 
Nineteen dietary phenolic compounds (anthocyanins, anthocyanidins and other phenolics) 1011 
were selected based on the phytochemical analysis by LC-MS/MS in the four freeze-dried 1012 








Measured in IVGD 
extracts 
1 Cyanidin 287.24 BC, GC, WT, MS DBC, DGC, DWT, DMS 
2 Delphinidin 303.24 BC, GC, WT, MS DBC, DGC, DWT, DMS 
3 Malvidin 331.30 GC, WT, MS DGC, DBC, DWT, DMS 
4 Cyanidin-3-glucoside  484.83 BC, WT, MS DBC, DWT, DMS 
5 Delphinidin-3-
glucoside 
500.83 BC, WT, MS DBC, DWT, DMS 
6 Malvidin-3-glucoside 493.43 WT, MS DWT, DMS 
7 Cyanidin-3-
galactoside 
449.39 WT, MS DWT, DMS 
8 Delphinidin-3-
galactoside 
500.84 WT, MS DWT, DMS 
9 Malvidin-3-
galactoside 
528.89 WT, MS DWT, DMS 
10 Cyanidin-3-
arabinoside 
419.36 GC, WT, MS DWT, DMS 
11 Protocatechuic Acid 154.12 BC, GC, WT, MS DBC, DGC, DWT, DMS 
12 Vanillic acid 168.14 BC, GC, WT, MS DBC, DGC, DWT, DMS 
13 Protocatechuic 
aldehyde 
138.12 BC, GC, WT, MS DBC, DGC, DWT, DMS 
14 Ferulic Acid 194.18 BC, GC, WT, MS DBC, DGC, DWT, DMS 
15 4-
hydroxybenzaldehyde 
122.12 BC, GC, WT, MS DBC, DGC, DMS 
16 Chlorogenic Acid 354.31 BC, GC, WT, MS DBC, DWT, DMS 
17 Gallic Acid 170.12 BC, GC, WT, MS DBC, DGC, DWT, DMS 
18 Syringic acid 198.17 BC, GC, MS DBC, DGC, DMS 




BC: Black currant, DBC: IVGD black currant, GC: Green currant, DGC: IVGD green 1015 
currant, WT: Wild type bilberry, DWT: IVGD wild type bilberry, MS: Mirtoselect, DMS: 1016 




Table 2: Molecular docking result of ligands (Gallic acid, Malvidin-3-glucoside and 1021 






















































Table 3. Molecular interaction analysis of ligands (obtained from molecular docking using 1028 
AutoDock) with PTP1B using BIOVIA Discovery Studio Visualizer 1029 
 1030 
Ligands Interacting pairs Distance Category Types 
Gallic acid A:GLY220:N - B:UNK0:O4 3.072 Hydrogen Bond Conventional Hydrogen Bond 
A:ARG221:N - B:UNK0:O5 3.30 Hydrogen Bond Conventional Hydrogen Bond 
A:ARG221:NE - B:UNK0:O5 2.93 Hydrogen Bond Conventional Hydrogen Bond 
B:UNK0:H18 - A:SER215:OG 2.04 Hydrogen Bond Conventional Hydrogen Bond 
B:UNK0:H16 - A:TYR46:OH 2.18 Hydrogen Bond Conventional Hydrogen Bond 
A:ALA217:CB - B:UNK0 3.47 Hydrophobic Pi-Sigma 
A:PHE182 - B:UNK0 5.15 Hydrophobic Pi-Pi T-shaped 
Malvidin-3-glucoside A:LYS120:NZ - B:UNK0:O5 3.02 Hydrogen Bond Conventional Hydrogen Bond 
A:ARG221:NE - B:UNK0:O12 2.89 Hydrogen Bond Conventional Hydrogen Bond 
B:UNK0:H45 - A:TYR46:OH 1.74 Hydrogen Bond Conventional Hydrogen Bond 
B:UNK0:H43 - A:ASP181:OD2 1.76 Hydrogen Bond Conventional Hydrogen Bond 
B:UNK0:H44 - A:ASP181:OD2 2.32 Hydrogen Bond Conventional Hydrogen Bond 
B:UNK0:H52 - A:ASP48:OD2 2.22 Hydrogen Bond Conventional Hydrogen Bond 
A:SER216:CB - B:UNK0:O10 2.71 Hydrogen Bond Carbon Hydrogen Bond 
A:GLY220:CA - B:UNK0:O9 2.75 Hydrogen Bond Carbon Hydrogen Bond 
A:ALA217:CB - B:UNK0 3.83 Hydrophobic Pi-Sigma 
B:UNK0:C34 - A:PHE182 3.67 Hydrophobic Pi-Sigma 
B:UNK0 - A:VAL49 5.21 Hydrophobic Pi-Alkyl 
B:UNK0 - A:ALA217 4.62 Hydrophobic Pi-Alkyl 
B:UNK0 - A:VAL49 4.93 Hydrophobic Pi-Alkyl 
Dephostatin A:SER216:N - B:UNK0:O1 2.69 Hydrogen Bond Conventional Hydrogen Bond 
A:ALA217:N - B:UNK0:O1 2.99 Hydrogen Bond Conventional Hydrogen Bond 
B:UNK0:H20 - A:GLU115:OE1 2.14 Hydrogen Bond Conventional Hydrogen Bond 
A:SER216:CB - B:UNK0:O3 3.04 Hydrogen Bond Carbon Hydrogen Bond 
B:UNK0:C9 - A:TYR46:OH 3.22 Hydrogen Bond Carbon Hydrogen Bond 
A:PHE182 - B:UNK0 4.68 Hydrophobic Pi-Pi T-shaped 
45 
 
B:UNK0 - A:ALA217 5.14 Hydrophobic Pi-Alkyl 
B:UNK0 - A:ARG221 4.89 Hydrophobic Pi-Alkyl 




Table 4 Various energy terms associated with MM/PBSA binding energy of Gallic acid, 1035 
Malvidin-3-glucoside and Dephostatin with PTP1B.  1036 
 1037 
Complexes Binding Energy Terms (kJ/mol) 
Vander 










Gallic acid -27.67±1.00 -
388.85±2.37 












Dephostatin -46.13± 1.06 -
227.34±2.61 


















Table 5. Inter-molecular contact analysis of the top ranked cluster of gallic acid (A) and 1051 
malvidin-3-glucoside –PTP1B (B) complexes obtained from the MD trajectories.  1052 
 1053 
Ligand Interacting pairs Distance Category Types 
Gallic acid A:SER215:HG - B:DRG299:O5 1.64 Hydrogen Bond Conventional Hydrogen Bond 
A:SER216:HN - B:DRG299:O4 2.77 Hydrogen Bond Conventional Hydrogen Bond 
A:ALA217:HN - B:DRG299:O4 1.89 Hydrogen Bond Conventional Hydrogen Bond 
A:GLY218:HN - B:DRG299:O5 2.22 Hydrogen Bond Conventional Hydrogen Bond 
A:ILE219:HN - B:DRG299:O5 2.15 Hydrogen Bond Conventional Hydrogen Bond 
A:GLY220:HN - B:DRG299:O5 1.79 Hydrogen Bond Conventional Hydrogen Bond 
A:GLY220:C,O;ARG221:N - B:DRG299 5.05 Hydrophobic Amide-Pi Stacked 
B:DRG299 - A:ALA217 5.48 Hydrophobic Pi-Alkyl 
Malvidin-3-
glucoside 
A:VAL49:HN - B:DRG299:O11 2.32 Hydrogen Bond Conventional Hydrogen Bond 
A:LYS116:CE - B:DRG299:O3 3.40 Hydrogen Bond Carbon Hydrogen Bond 
B:DRG299:C34 - A:GLU115:OE2 3.73 Hydrogen Bond Carbon Hydrogen Bond 
B:DRG299:C35 - B:DRG299:O5 3.67 Hydrogen Bond Carbon Hydrogen Bond 
A:PHE182 - B:DRG299 5.19 Hydrophobic Pi-Pi T-shaped 
B:DRG299 - A:ALA217 4.37 Hydrophobic Pi-Alkyl 
B:DRG299 - A:ILE219 5.24 Hydrophobic Pi-Alkyl 
B:DRG299 - A:VAL49 4.64 Hydrophobic Pi-Alkyl 
B:DRG299 - A:ALA217 5.25 Hydrophobic Pi-Alkyl 
B:DRG299 - A:ILE219 5.31 Hydrophobic Pi-Alkyl 
B:DRG299 - A:LYS116 4.71 Hydrophobic Pi-Alkyl 
B:DRG299 - A:ALA217 5.31 Hydrophobic Pi-Alkyl 
*DRG: Corresponding ligand 1054 
